Golcadomide

Tier C — Watch / trade

Golcadomide

Celgene Corporation

Originator

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：IKZF1, IKZF3

Indications (approved)：Follicular lymphoma, Diffuse large B-cell lymphoma, 大B细胞淋巴瘤, Mantle cell lymphoma, Peripheral T-cell lymphoma, B-cell lymphoma, T-cell lymphoma, Non-Hodgkin lymphoma

Regional status

Phase III

2024-06-19

Phase III

2024-06-19

China

Phase III

2024-06-19

Japan

Phase III

2024-06-19

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Golcadomide?

Approved indications include: Follicular lymphoma, Diffuse large B-cell lymphoma, 大B细胞淋巴瘤, Mantle cell lymphoma, Peripheral T-cell lymphoma, B-cell lymphoma, T-cell lymphoma, Non-Hodgkin lymphoma.

When does the Golcadomide patent expire?

No public expiry year is available for Golcadomide yet; this page updates once verified.

How do I get a quote for Golcadomide intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-01